ReviewJournal of nanobiotechnology2025
Nanosensitizer-assisted sonodynamic therapy for breast cancer.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Endogenous Albumin-Mediated Disassembly of Phthalocyanine Nanoparticles for Tumor-Selective Imaging and Sonodynamic Therapy.Chemical & biomedical imaging · 2026Article
- Ultrasound-responsive biomimetic nanocarrier triggers spatiotemporal PROTAC release and ROS storm to disrupt TNBC immunosuppression via coordinated apoptosis/ferroptosis/senescence activation.Journal of nanobiotechnology · 2026Article
- A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy.Materials today. Bio · 2026Article
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
- An Active-Targeted ZIF8-Based Nanotheranostic Platform for Ultrasound Imaging-Guided Synergistic Therapy of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Article
- Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.Frontiers in immunology · 2026Review
- Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review.Breast cancer (Dove Medical Press) · 2026Review
- The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.Frontiers in pharmacology · 2026Review
- Exosome-Enhanced Sonodynamic Therapy in Cancer: Emerging Synergies and Modulation of the Tumor Microenvironment.Cancers · 2025Review
- Low-intensity pulsed ultrasound (LIPUS)-augmented calcicoptosis by calcium-based nanoparticles for enhanced immunogenic cell death induction in triple-negative breast cancer.Journal of nanobiotechnology · 2025Article
- Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.ACS biomaterials science & engineering · 2025Review
- Ultrasound-Responsive Drug Delivery System Based on Piezoelectric Catalytic Mechanisms.Journal of functional biomaterials · 2025Article
- Research progress on the induction of immunogenic cell death in tumor immunotherapy using a sonodynamic therapy nanoparticle delivery system.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most commonly diagnosed cancer worldwide. Despite advancements in therapeutic modalities, its prognosis remains poor owing to complex clinical, pathological, and molecular characteristics. Sonodynamic therapy (SDT) is a promising approach for tumor elimination, using sonosensitizers that preferentially accumulate in tumor tissues and are activated by low-intensity ultrasound to produce reactive oxygen species. However, the clinical translation of SDT faces challenges, including the limited efficiency of sonosensitizers and resistance posed by the tumor microenvironment. The emergence of nanomedicine offers innovative strategies to address these obstacles. This review discusses strategies for enhancing the efficacy of SDT using sonosensitizers, including rational structural modifications, improved tumor-targeted enrichment, tumor microenvironment remodeling, and imaging-guided therapy. Additionally, SDT-based multimodal therapies, such as sono-chemotherapy, sono-immunotherapy, and sono-photodynamic therapy, and their potential applications in breast cancer treatment are summarized. The underlying mechanisms of SDT in breast cancer are briefly outlined. Finally, this review highlights current challenges and prospects for the clinical translation of SDT, providing insights into future advancements that may improve therapeutic outcomes for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.